During a live event, Nizar M. Tannir, MD and participants discussed how they think ahead to later lines of therapy when ...

Survival and Progression Metrics: Secondary and exploratory endpoints include duration of response, sustained MRD negativity, biochemical and clinical progression-free survival (PFS), time to a ...

Mitazalimab, in combination with standard chemotherapy, has exhibited continued promising efficacy and safety in treating ...

Michael Cole shares his decade-long battle with malignant pleural mesothelioma, highlighting treatment choices, resilience, and the vital doctor-patient relationship.

Combination therapy with relatlimab and nivolumab enhances treatment-free survival in advanced melanoma, offering promising ...

The study evaluated lifileucel in patients 18 years and older with unresectable or metastatic melanoma (stage IIIc or IV) who ...

The JAVELIN Bladder 100 trial established avelumab (Bavencio) as a standard switch maintenance therapy, according to Grivas.

FDA lifts REMS program for vandetanib, affirming safety in thyroid cancer treatment as healthcare providers ensure effective ...

During a live event, Ann F. Mohrbacher, MD, reviewed treatment options for a patient with early relapsed diffuse large B-cell ...

The US FDA has approved imlunestrant (Inluriyo) for the treatment of adult patients with estrogen receptor (ER)-positive, ...

Daratumumab-based regimens show significant clinical benefits for newly diagnosed, transplant-ineligible multiple myeloma ...

Preliminary Kaplan-Meier analyses, presented at the American Association for Cancer Research (AACR) 7th Biennial Special ...